QNCX

Quince TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.20

+109.5% vs current

Most likely

Base case

45%

Probability

Target price

$0.90

-14.3% vs current

B-

Bear case

30%

Probability

Target price

$0.35

-66.7% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Sentiment is cautious and monitoring-oriented. Primary sources now point to a failed lead program, a restructuring/strategic review, debt cleanup, and a reverse split rather than a traditional development story [#PR-2026-01-29][#PR-2026-02-09][#PR-2026-03-30][#8-K-2026-04-09]. That creates real optionality if a transaction emerges, but the deterministic prior is still negative and the 10-K going-concern language keeps conviction capped [#10-K-2026-04-10].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-31catalystPost-reverse-split trading and listing stabilizationHigh impact

Quince filed an 8-K on April 9, 2026 stating the 1-for-10 reverse stock split became effective at 11:59 p.m. Eastern Time on April 10, 2026 and split-adjusted trading began April 13, 2026; near-term price action and liquidity after the split are likely to drive technical volatility around the listing-stability narrative [#8-K-2026-04-09].

2026-09-30eventStrategic alternative outcome after debt cleanupHigh impact

Quince engaged LifeSci Capital on February 9, 2026 to evaluate restructuring and strategic alternatives, and on March 30, 2026 said the $5.5 million EIB settlement fully discharged roughly $16.4 million of debt and removed an overhang that had constrained flexibility; the next material step is a disclosed transaction such as a merger, reverse merger, asset sale, partnership, or similar action [#PR-2026-02-09][#PR-2026-03-30].

2027-04-10catalystRunway and funding pressure remain centralHigh impact

The 2026-04-10 10-K says Quince had $17.8 million of cash, cash equivalents and short-term investments at December 31, 2025, raised about $20.4 million after year-end through the ATM, and still has substantial doubt about continuing as a going concern while needing additional funding to execute a strategic transaction; that makes financing terms or merger economics a major medium-term driver [#10-K-2026-04-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology